Adaptive Biotechnologies Corp
ADPTNasdaq
$22.92
↑ +3.7%Jul 17 close · end-of-day
Price
1Y↑ +111.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.6B
Enterprise Value
$3.5B
P/E
—
P/S
12.1
P/B
16.5
EV/EBITDA
—
PEG
—
FCF Yield
-0.8%
Dividend Yield
—
Revenue (TTM)
$295.4M
Net Income (TTM)
-$49.7M
Free Cash Flow (TTM)
-$29.5M
Gross Margin
—
Operating Margin
-15.8%
Net Margin
-16.8%
ROE
-23.0%
ROIC
-28.7%
Debt / Equity
0.6
Net Cash
$87.8M
Return 1Y
+118.3%
Company profile
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It serves the life sciences research, clinical diagnostics, and drug discovery applications.
- CEO
- Chad Robins
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 790
- Headquarters
- Washington
- Website
- adaptivebiotech.com
Management & directors
- Lo FrancisChief People Officer
- Robins Harlan SChief Scientific Officer
- Bobulsky SusanChief Commercial Officer, MRD
- Benzeno SharonChief Commercial Ofc Imm Med
- Piskel KyleChief Financial Officer
- Rubinstein JuliePresident and COO
- Robins Chad MCEO and Chairman
Roles derived from SEC Form 4 filings.
Earnings
ADPT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$70.9M↑ +35.1%
Diluted EPS-$0.13↓ -35.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $98.4M | $154.3M | $185.3M | $170.3M | $179.0M | $277.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$152.8M | -$209.0M | -$200.2M | -$227.0M | -$162.5M | -$57.1M |
| Net income | -$146.2M | -$207.3M | -$200.2M | -$225.3M | -$159.5M | -$59.5M |
| Diluted EPS | -$1.11 | -$1.48 | -$1.40 | -$1.56 | -$1.08 | -$0.39 |
| Operating cash flow | -$149.7M | -$192.7M | -$183.9M | -$156.3M | -$95.2M | -$46.0M |
| Free cash flow | -$168.5M | -$254.5M | -$200.3M | -$167.0M | -$98.9M | -$48.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -155.3% | -135.4% | -108.0% | -133.3% | -90.8% | -20.6% |
| Net margin | -148.6% | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $43.2M | $46.4M | $47.5M | $52.4M | $58.9M | $94.0M | $71.7M | $70.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$47.3M | -$32.6M | -$33.8M | -$29.6M | -$25.0M | $10.3M | -$12.8M | -$19.2M |
| Net income | -$46.2M | -$32.1M | -$33.7M | -$29.9M | -$25.6M | $9.5M | -$13.6M | -$20.0M |
| Diluted EPS | -$0.31 | -$0.22 | -$0.22 | -$0.20 | -$0.17 | $0.06 | -$0.08 | -$0.13 |
| Operating cash flow | -$17.3M | -$27.1M | -$12.5M | -$28.5M | -$12.4M | -$7.1M | $2.1M | -$9.5M |
| Free cash flow | -$19.0M | -$27.4M | -$12.6M | -$29.7M | -$13.1M | -$7.5M | $1.4M | -$10.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -109.6% | -70.3% | -71.3% | -56.4% | -42.5% | 10.9% | -17.8% | -27.1% |
| Net margin | -107.0% | -69.1% | -71.0% | -56.9% | -43.5% | 10.2% | -18.9% | -28.3% |
Company news
Jul 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | LO FRANCIS· Chief People Officer | Sale | 105,762 | $22.59 | $2.4M | filing |
| 2026-07-15 | LO FRANCIS· Chief People Officer | Option exercise | 59,374 | $7.80 | $463,117.20 | filing |
| 2026-07-15 | LO FRANCIS· Chief People Officer | Option exercise | 23,677 | $12.14 | $287,438.78 | filing |
| 2026-07-15 | LO FRANCIS· Chief People Officer | Option exercise | 22,711 | $8.46 | $192,135.06 | filing |
| 2026-07-02 | ROBINS HARLAN S· Chief Scientific Officer | Sale | 239,351 | $21.74 | $5.2M | filing |
| 2026-07-02 | ROBINS HARLAN S· Chief Scientific Officer | Sale | 146,889 | $22.45 | $3.3M | filing |
| 2026-07-02 | LO FRANCIS· Chief People Officer | Sale | 44,838 | $22.59 | $1.0M | filing |
| 2026-07-02 | LO FRANCIS· Chief People Officer | Option exercise | 12,600 | $12.14 | $152,964.00 | filing |
| 2026-07-02 | LO FRANCIS· Chief People Officer | Option exercise | 12,637 | $8.46 | $106,909.02 | filing |
| 2026-07-02 | LO FRANCIS· Chief People Officer | Option exercise | 12,626 | $7.80 | $98,482.80 | filing |
| 2026-07-01 | LO FRANCIS· Chief People Officer | Sale | 42,261 | $22.50 | $950,872.50 | filing |
| 2026-07-01 | LO FRANCIS· Chief People Officer | Sale | 8,743 | $22.18 | $193,919.74 | filing |
| 2026-07-01 | LO FRANCIS· Chief People Officer | Option exercise | 14,064 | $8.12 | $114,199.68 | filing |
| 2026-07-01 | LO FRANCIS· Chief People Officer | Option exercise | 12,206 | $8.46 | $103,262.76 | filing |
| 2026-07-01 | LO FRANCIS· Chief People Officer | Option exercise | 3,300 | $12.14 | $40,062.00 | filing |
| 2026-07-01 | LO FRANCIS· Chief People Officer | Option exercise | 3,500 | $7.80 | $27,300.00 | filing |
| 2026-07-01 | LO FRANCIS· Chief People Officer | Option exercise | 4,688 | $3.99 | $18,705.12 | filing |
| 2026-07-01 | BOBULSKY SUSAN· Chief Commercial Officer, MRD | Sale | 487 | $22.00 | $10,714.00 | filing |
| 2026-06-29 | BENZENO SHARON· Chief Commercial Ofc Imm Med | Sale | 154,768 | $21.14 | $3.3M | filing |
| 2026-06-29 | BENZENO SHARON· Chief Commercial Ofc Imm Med | Option exercise | 51,570 | $8.12 | $418,748.40 | filing |
| 2026-06-29 | BENZENO SHARON· Chief Commercial Ofc Imm Med | Option exercise | 24,944 | $8.46 | $211,026.24 | filing |
| 2026-06-29 | BENZENO SHARON· Chief Commercial Ofc Imm Med | Option exercise | 24,944 | $3.99 | $99,526.56 | filing |
| 2026-06-29 | BENZENO SHARON· Chief Commercial Ofc Imm Med | Option exercise | 1,837 | $12.14 | $22,301.18 | filing |
| 2026-06-26 | BENZENO SHARON· Chief Commercial Ofc Imm Med | Sale | 11,034 | $21.00 | $231,714.00 | filing |
| 2026-06-26 | BENZENO SHARON· Chief Commercial Ofc Imm Med | Option exercise | 11,034 | $12.14 | $133,952.76 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.